BOSTON, Jan. 6, 2015 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) (“Columbia” or “the Company”), a specialty pharmaceutical company focused on pharmaceuticals for women’s health, today announced the appointment of Dr. Bridget A. Martell, 49, to the newly created position of Chief Medical Officer, effective immediately. The appointment is an important step in Columbia’s focus on advancing a proprietary drug program. The Company expects to advance its next product candidate COL-1077, an extended release lidocaine gel for the treatment of gynecological procedure related pain, into clinical trials this year. Columbia continues to receive product revenue and royalties from its initial commercial product, Crinone ®, a vaginal progesterone gel used in fertility treatment.
“Bridget has extensive experience managing clinical development and medical affairs activities for leading pharmaceutical companies, making her the ideal candidate to oversee the resumption of our proprietary product development program. Her successful track record of advancing novel formulations through clinical development and regulatory approval will benefit Columbia as we prepare COL-1077 for clinical trials and evaluate other new products and technologies in women’s health,” said Frank Condella, Columbia’s president and chief executive officer.
Dr. Martell brings more than 15 years’ experience in clinical development, medical affairs and academia to Columbia, including expertise in establishing regulatory strategy for clinical programs and creating submission readiness packages. She has overseen the product development activities of numerous pharmaceutical companies, including Purdue Pharma and several business units within Pfizer Worldwide’s biopharmaceutical business. At Purdue Pharma, Dr. Martell led and built a new medical affairs organization to support the in-line and developing medications portfolio. Prior to that Dr. Martell was the Biosimilars medical head at Pfizer, responsible for clinical development and medical affairs activities. She also held senior clinical development roles at other business units within Pfizer’s biopharmaceutical business. Most recently, Dr. Martell was the founder and managing director of BAM Consultants, which provides clinical development and medical affairs consulting services to a broad array of specialty pharmaceutical companies.
Dr. Martell holds a Bachelor of Science from Cornell University, Master of Arts from Boston University, and a Doctor of Medicine degree from The Chicago Medical School. She completed her internship and residency in Internal Medicine, was a Chief Resident, and a Robert Wood Johnson Clinical Scholar at Yale University School of Medicine. She is board certified in both Internal and Addiction Medicine.
About Columbia Laboratories
Columbia Laboratories, Inc. has a successful heritage in developing women’s health focused pharmaceutical products, including CRINONE® 8% (progesterone gel), that is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 additional countries worldwide. Columbia is leveraging its pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to advance an internal pipeline while generating revenue from pharmaceutical industry customers. For more information, please visit www.columbialabs.com.
CRINONE® is a registered trademark of Actavis, Inc. in the U.S.
Forward Looking Statements
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are usually indicated by the words “may,” “will,” “plans,” “believes,” “expects,” “anticipates,” “potential,” “should,” or similar expressions, and which are generally not historical in nature. These include all statements relating to expected financial performance and future business or product developments. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management’s current expectations and Columbia does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law. For a discussion of certain risks and uncertainties associated with Columbia’s forward-looking statements, please review Columbia’s reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2013.
Contact:
Katja Buhrer
MBS Value Partners
(212) 661-7004
katja.buhrer@mbsvalue.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/columbia-laboratories-announces-appointment-of-chief-medical-officer-300016118.html
SOURCE Columbia Laboratories, Inc.
Help employers find you! Check out all the jobs and post your resume.
